Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 2.37M shares outstanding
USLakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs.
It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial.
The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Kelvin Cooper
CEO, SVP of Research & Development and Director
Thomas Balzer
Chief Medical Officer & SVP of Clinical Development
Peter F. Ceccacci
CFO & VP of Administration
Daniel Kontoh-Boateng
Investor Relations
Employees
5
Country
US
Sector
Healthcare
Website
lakewoodamedex.com
Loading congressional disclosures…
based on 2.37M shares outstanding
US30d Avg
2.41M
60d Avg
1.80M
90d Avg
2.53M
